Background
Phase 3, open-label RCT (GHSG HD14). N=1,686 patients with newly diagnosed early-stage unfavorable classical Hodgkin lymphoma (stage IA/IIB with bulky mediastinum or extranodal involvement, or stage IIA/B with ≥3 nodal areas, elevated ESR, or bulky disease by GHSG criteria). All patients received 30 Gy involved-field RT after completing chemotherapy.
Interventions and follow up
Arm A: 4×ABVD + 30 Gy IF-RT (n=844)
Arm B: 2+2 regimen — 2×BEACOPPesc + 2×ABVD + 30 Gy IF-RT (n=842)
Primary endpoint: Freedom from treatment failure (FFTF)
Median follow-up: ≥10 years (Gillessen et al, Lancet Haematol 2021)
Arm B: 2+2 regimen — 2×BEACOPPesc + 2×ABVD + 30 Gy IF-RT (n=842)
Primary endpoint: Freedom from treatment failure (FFTF)
Median follow-up: ≥10 years (Gillessen et al, Lancet Haematol 2021)
Results
5-yr FFTF (2+2 vs ABVD): 91.2% vs 85.0%, HR 0.56 (95% CI 0.36–0.86), P=.003
10-yr PFS: persistent superiority of 2+2 confirmed at ≥10 years (Gillessen 2021)
OS: no significant difference between arms at long-term follow-up (>95% both groups)
10-yr PFS: persistent superiority of 2+2 confirmed at ≥10 years (Gillessen 2021)
OS: no significant difference between arms at long-term follow-up (>95% both groups)
Adverse events
Hematologic: Grade ≥3 leukopenia 79% (2+2) vs 33% (ABVD); grade ≥3 thrombocytopenia 38% vs 5%
Late effects: Secondary MDS/AML 7 cases (2+2) vs 3 cases (ABVD); higher infertility risk with BEACOPPesc due to alkylating agents; treatment-related mortality <1% both arms
Late effects: Secondary MDS/AML 7 cases (2+2) vs 3 cases (ABVD); higher infertility risk with BEACOPPesc due to alkylating agents; treatment-related mortality <1% both arms
Conclusions
The 2+2 regimen (2×BEACOPPesc + 2×ABVD + IF-RT) significantly improved FFTF compared to 4×ABVD + IF-RT in early-stage unfavorable cHL, with persistent superiority confirmed at ≥10 years, establishing it as the standard intensive approach in Germany and influencing European guidelines.
Key Limitations
FFTF superiority without an OS benefit limits the risk-benefit justification for the more toxic 2+2 regimen given equivalent survival. BEACOPPesc carries meaningful risks of secondary MDS/AML (absolute excess ~7 cases/800 patients), gonadotoxicity, and significant hematologic toxicity not captured by FFTF. The 2+2 regimen is rarely used outside GHSG centers — US and UK guidelines favor ABVD-based approaches. No PET-adapted de-escalation was incorporated; HD17 subsequently demonstrated RT can be omitted after 2+2 in PET4-negative patients.
Clinical Context
HD14 established the 2+2 regimen as the GHSG/ESMO standard for early-stage unfavorable cHL. The subsequent HD17 trial demonstrated that RT can be safely omitted in 2+2-treated patients who are PET4-negative (5-yr PFS 95.1% vs 97.3%), creating a chemotherapy-only pathway for the majority of these patients. In the US, ABVD × 4 cycles + involved-site RT (30–36 Gy) is favored, with BEACOPPesc reserved for high-risk unfavorable cases. ESMO-MCBS: not assigned.